Drug Trial Radar · NCT00185159
Olmesartan Medoxomil in Diabetes Mellitus
Last checked: Nov 20, 2026Latest source record: Jan 20, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,449
Actual
Start
Oct 2004
Primary completion
Jul 2009
Study completion Jul 2009
Sponsor
- Lead sponsor
- Sankyo Pharma GmbhIndustry
- Sponsor type
- Industry
- First posted
- Sep 16, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study in diabetic patients with at least one additional cardiovascular risk factor and normoalbuminuria prior to randomization.
Conditions
- Diabetes Mellitus, Type 2
- Cardiovascular Disease
- Kidney Disease
Interventions
Olmesartan medoxomilDrug
tablets
Placebo TabletsDrug
Tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to the first occurrence of microalbuminuria defined as excretion of greater than 35 mg albumin/g urine creatinine for women and greater than 25 mg albumin/g urine creatinine for men in morning spot urineTime frame: Time to the first occurrence
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site not named
Darmstadt, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.